Login:
 
Ranolazine effective for angina in diabetes patients with high CVD risk. Practitioner 2013; 257 (1760): 10

Ranolazine effective for angina in diabetes patients with high CVD risk

25 Apr 2013Registered users

Ranolazine, a sodium channel blocker, significantly improved angina in patients with diabetes and coronary artery disease (CAD), a randomised, double-blind trial has found.

Registered usersThis article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.

To buy this article (£25+tax) copy the article citation above and click Buy article